Nauticus Robotics has expanded to the United Kingdom and to Norway. Image via nauticusrobotics.com

A Webster-based tech company has officially launched operations in two European countries — and it's only the beginning.

Nauticus Robotics Inc. (NASDAQ: KITT), which went public a few months ago, opened operations in Norway and the United Kingdom, "beginning the company’s international expansion strategy for 2023 and beyond," according to a release from Nauticus. The company develops underwater robots, software, and services to the marine industries.

“The ocean touches nearly every aspect of our lives, yet paradoxically seems to receive less attention and innovation when compared to other sectors,” says Nicolaus Radford, founder and CEO of Nauticus, in the release. “As we expand our operations to these strategic locales and beyond, our core mission remains the same: to become the most impactful ocean robotics company and realize a future where autonomous robotic technologies are commonplace and enable the blue economy for the better."

The two new operating bases are in Stavanger, Norway, and Aberdeen, Scotland. The two outposts will serve the North Sea offshore market. According to the release, Nauticus will work with local partners to service the region’s offshore wind and oil and gas markets. The company will also expand Nauticus Fleet, a "robotic navy of surface and subsea robots," which was established in April of 2022.

These two new regional offices are just the first examples of international growth Nauticus has planned, according to the release. Established to serve as logistics operation centers, the company's expansion plan includes new remote operation centers and service teams around the world in growth markets. The company did not announce any specific expansion plans.

"We are eager to ramp up activities in these international markets as our growing team contributes to our mission," Radford adds.

In October, shortly after its IPO, Nauticus announced that it has been awarded a second multimillion-dollar contract from the U.S. Defense Innovation Unit, part of the U.S. Defense Department, for development of a self-piloted amphibious robot system powered by the company’s ToolKITT command-and-control software.

The company was originally founded in 2014 as Houston Mechatronics Inc. before rebranding in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”